导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.68% | 3966/4773 |
| 近一周 | -2.11% | 3404/5465 |
| 近一月 | -5.17% | 3647/5421 |
| 近一季 | 4.18% | 397/5231 |
| 近半年 | -8.48% | 3514/4920 |
| 近一年 | -19.63% | 3933/4394 |
| 近两年 | 10.27% | 2801/2954 |
| 近三年 | -14.13% | 2074/2253 |
| 成立以来 | 34.73% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.27% 4219/4961 |
-8.67% 3909/5312 |
- - |
- - |
| 2025 | 4.27% 3056/4813 |
0.14% 1968/3635 |
-1.60% 3225/4076 |
15.12% 2843/4524 |
-8.07% 3871/4813 |
| 2024 | 0.17% 2084/3463 |
-2.83% 1442/2808 |
-7.66% 2107/3014 |
17.13% 1267/3129 |
-4.68% 2489/3463 |
| 2023 | -15.45% 1650/2656 |
-0.42% 1793/2280 |
-9.04% 2028/2385 |
-0.40% 418/2515 |
-6.27% 1697/2655 |
| 2022 | -18.07% 658/2207 |
-17.68% 1239/1919 |
12.08% 247/2016 |
-13.98% 1006/2113 |
3.23% 744/2208 |
| 2021 | -7.16% 1031/1822 |
-6.06% 974/1255 |
9.26% 572/1330 |
-11.56% 1271/1466 |
2.28% 635/1822 |
| 2020 | 74.61% 57/1250 |
-0.15% 181/1028 |
25.06% 162/1067 |
18.51% 82/1164 |
18.00% 108/1184 |
| 2019 | 38.82% 297/1092 |
24.19% 526/739 |
2.18% 94/788 |
4.09% 218/850 |
5.09% 750/918 |
| 2018 | -22.81% 260/834 |
- - |
0.13% 40/631 |
-7.90% 472/660 |
-15.77% 622/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 招商上证消费80ETF联接C VS. 长安沪深300非周期A(740101) |